Cargando…
Chemoradiotherapy for Small-Cell Prostate Carcinoma: A Case Report
A 60-year-old male with small-cell prostate carcinoma (SCPC) received external-beam radiotherapy of 60 Gy in 30 fractions and chemotherapy (cisplatin (CDDP) 80 mg/m(2) + etoposide (VP-16) 100 mg/m(2), six courses). Although fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET...
Autores principales: | Makita, Kenji, Hamamoto, Yasushi, Nagasaki, Kei, Kanzaki, Hiromitsu, Hashine, Katsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165937/ https://www.ncbi.nlm.nih.gov/pubmed/37168181 http://dx.doi.org/10.7759/cureus.37287 |
Ejemplares similares
-
Relationship between seminal vesicle displacement and distribution of hydrogel spacer within the perirectal space in prostate radiotherapy
por: Makita, Kenji, et al.
Publicado: (2023) -
Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer
por: Makita, Kenji, et al.
Publicado: (2023) -
Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer
por: Kanzaki, Hiromitsu, et al.
Publicado: (2021) -
Local control of bone metastasis treated with palliative radiotherapy in patients with lung cancer: An observational retrospective cohort study
por: Makita, Kenji, et al.
Publicado: (2023) -
An easy tool to predict survival in patients with bone metastatic lung cancer treated with palliative radiotherapy
por: Makita, Kenji, et al.
Publicado: (2023)